Due to its contribution to fibrinolysis, tissue<unk>  is used medically to treat blood clot-related disorders including thrombotic or embolic stroke, myocardial infarction, and pulmonary embolism. It is manufactured using recombinant techniques and is sold as alteplase, reteplase, and tenecteplase. Alteplase was the first of these versions to go on the market, and has the same exact structure as tPA. Reteplase and tenecteplase both received FDA approval after alteplase, and have nonidentical structures to tPA. These recombinant forms of tPA have been shown to have a longer half-life in the blood and a greater resistance to inhibition, resulting in an increased capacity to treat thrombolytic diseases. Urokinase is similarly used in the medical field, specifically for the treatment of pulmonary embolism.
Plasminogen activator
Endopeptidase inhibitor
Tissue factor pathway inhibitor
Fibrinolysis
Thrombolysis
Exopeptidase inhibitor
Anticoagulant
Anistreplase